Medical Capability Explainer
China’s Progress in Advanced Cardiac Procedures
What international patients should know about TAVR, complex coronary intervention and atrial fibrillation ablation.
Published · Evidence and sources checked 30 September 2026
What the evidence says about capability
China's advanced cardiac care can be assessed through published trials, hospital datasets, specialist guidance and domestic device approvals. These sources provide a basis for considering a second opinion or planned specialist evaluation. They do not establish a single national cure rate, nor do they determine whether an individual can safely travel.
This guide focuses on selected valve interventions, coronary procedures and electrophysiology. If you suspect a heart attack, contact local emergency services immediately, including when symptoms are uncertain. Chest discomfort with breathlessness or other concerning symptoms should not wait for an overseas consultation. [11]
China has published TAVR guidance and procedure-specific studies. Coronary research includes randomized trials of imaging guidance and complex bifurcation strategies, while Chinese centers have studied newer AF ablation systems. [1] [4] [5] [6] [7]
The 2025 cardiovascular report summary, published in 2026, reports 2024 HQMS coronary-heart-disease hospitalization data: 2.211 million patients undergoing PCI and 0.6% in-hospital mortality among PCI patients. This is reporting-context data—not an elective international-patient risk estimate or a procedure-specific death rate. [14]
The practical question is which team, procedure and follow-up pathway fit the patient. National scale alone cannot answer that question.
TAVR and structural heart intervention
TAVR places a replacement aortic valve using a catheter, avoiding conventional open-heart valve replacement. It is used for selected patients with aortic valve disease, particularly aortic stenosis. A catheter approach still carries risks and requires careful planning. [12]
A heart-team assessment should address diagnosis, anatomy, alternatives and expected benefit. Chinese guidance supports structured evaluation, but does not prove that every institution has identical resources or outcomes. [1]
In February 2025, NMPA announced approval of the Prizvalve system for symptomatic, calcified, severe degenerative aortic stenosis in patients aged at least 70 who were judged unsuitable for conventional surgery by a heart team. Those are the stated conditions for that product—not an age rule for every TAVR device. [2]
Ask which valve is proposed, why it fits the anatomy, what alternatives remain and how complications are managed. Results for aortic-valve treatment should not be transferred to mitral or tricuspid procedures.
Published TAVR safety outcomes
A 2023 Chinese study included 156 patients treated from January 2022 to April 2023 with VenusA-Pro or VenusA-Plus delivery systems. It combined a prospective Pro cohort with a retrospective Plus comparison group; patients were not randomized. The following outcomes were reported at 30 days. [3]
| Outcome | Events | Reported percentage |
|---|---|---|
| All-cause death | 4 | 2.6% |
| Stroke | 1 | 0.6% |
| Major bleeding | 6 | 3.8% |
| Major vascular complications | 8 | 5.1% |
| Permanent pacemaker implantation | 8 | 5.1% |
These are selected outcomes from a specific study, not a complete risk list or current nationwide rates. Events can overlap, so the percentages must not be added. Thirty-day death is not intraoperative death, and these results cannot predict long-term valve durability. [3]
Coronary intervention and complex PCI
PCI treats narrowed coronary arteries, commonly using a stent. For planned treatment, ask why intervention is proposed and how it compares with medication or surgery for the individual patient.
The 2018 ULTIMATE randomized trial enrolled 1,448 patients requiring drug-eluting stents. At 12 months, target-vessel failure occurred in 21 patients (2.9%) with intravascular-ultrasound guidance and 39 (5.4%) with angiography guidance. This endpoint combined cardiac death, target-vessel heart attack and clinically driven repeat treatment; it was not a mortality rate or every complication. [4]
The China-led international DEFINITION II trial randomized 653 patients across 49 centers. At one year, target-lesion failure was 6.1% with a planned two-stent approach and 11.4% with provisional stenting; cardiac death did not differ significantly. This supports technique-specific planning for lesions meeting the trial criteria—not a rule that two stents are always better. [5]
These studies demonstrate research capability and the importance of procedure selection. They do not mean that a stent cures the underlying tendency to cardiovascular disease or removes the need for ongoing care.
Atrial fibrillation ablation and newer technology
AF ablation seeks to control abnormal rhythm. Immediate electrical isolation differs from remaining free of arrhythmia during later follow-up. Treatment goals should include symptoms, recurrence and medication requirements, rather than a single claim of cure.
The 2025 InsightPFA randomized trial enrolled 287 patients at 13 Chinese centers. In the full analysis set, its standardized 12-month primary endpoint was reached by 93/142 patients (65.5%) receiving nanosecond pulsed-field ablation and 93/145 (64.1%) receiving guided radiofrequency ablation. The trial met noninferiority, not superiority. Both groups achieved 100% acute procedural success, illustrating the difference between immediate and later outcomes. [6]
The 2024 single-arm PLEASE-AF study involved 143 patients at 12 Chinese hospitals. It reported 12-month freedom from atrial arrhythmias lasting at least 30 seconds in 124/143 patients (86.7%). One patient developed a small pericardial effusion one month later without needing intervention. That event is not an overall complication rate, and different designs and endpoints prevent direct ranking against InsightPFA. [7]
Follow-up is part of the procedure
A 2024 Chinese consensus addresses care around TAVR assessment, procedure and recovery. It demonstrates organized professional work, not identical practice at every center. [8]
After a coronary stent, take prescribed medicines and attend follow-up. Antiplatelet treatment helps prevent clots in the stent. [10] After AF ablation, anticoagulation decisions depend on individual thromboembolic risk even if normal rhythm has been restored. Do not stop medication because a procedure appeared successful. [9]
Before travel, agree who will monitor recovery, prescribe medicines and respond to complications at home. Keep procedure reports, device information and the discharge plan available to the receiving clinician. [13]
How to compare outcomes responsibly
| Measure | What to clarify |
|---|---|
| Mortality | During the procedure, before discharge, at 30 days or later? |
| Stroke or bleeding | Which definition, severity and observation period? |
| Repeat intervention | Planned staged treatment or an unplanned additional procedure? |
| AF treatment success | Acute electrical isolation or sustained rhythm outcome, with or without medication? |
| Composite endpoint | Which events are combined, and did individual components differ? |
Ask for results in patients with similar diagnoses and risk profiles. Do not compare percentages across unrelated procedures as a safety league table. Lower short-term mortality alone does not prove better symptom relief or long-term health.
Planned evaluation, travel and costs
A stable patient may seek a second opinion about valve intervention, complex coronary treatment or AF ablation. Stability and travel fitness must be confirmed clinically; this website cannot certify either. Acute coronary symptoms and other unstable conditions require timely local assessment. [11]
Ask the receiving institution which records it needs. Available echocardiography, angiography images and reports, ECG or rhythm-monitoring reports, prior procedure notes and a current medication list can help frame the question. Confirm a private channel before submitting sensitive records.
Obtain an itemized estimate separating assessment, device, hospital care, medicines and follow-up from interpretation, accommodation and transport. Clarify responsibility for added treatment or an extended stay. This article does not verify price, waiting time or insurance coverage.
Hospital discharge and fitness for a long flight are different decisions. Arrange continuity of care before departure. [13]
How MedVoyage China can help
MedVoyage China can help organize non-clinical case information, coordinate questions with institutions and clarify appointments and practical arrangements. Licensed cardiovascular professionals remain responsible for diagnosis, urgency, procedure choice and travel fitness. Hospital acceptance, availability and outcomes are not guaranteed.
Begin with the decision you need help understanding. Confirm an agreed private channel before sending detailed records. For suspected emergencies, contact local emergency services rather than waiting for a coordination response.
Questions & answers
Is TAVR available in China?
China has published TAVR clinical guidance, device approvals and clinical studies. These establish capability, but current access depends on the institution and proposed device. A heart-team assessment is needed to determine whether TAVR or another approach is appropriate for the particular patient. [1][2]
Does a domestic valve approval mean I am eligible?
No. Approval applies to a particular product and its indications. For example, the cited Prizvalve announcement describes a specific age and clinical population. The institution must assess your condition and confirm the relevant current device indication; another product may have different requirements. [2]
Does successful PCI mean no further treatment is needed?
No. Follow-up and prescribed medicines remain important. Antiplatelet treatment can help prevent a clot in the stent. Ask the clinician for a written medication and monitoring plan, including what to do if a problem occurs, and do not change treatment on the basis of this article. [10]
Is pulsed-field ablation a guaranteed cure for AF?
No. The cited Chinese trials distinguish immediate procedural results from outcomes during follow-up. Recurrence can still occur. Published percentages depend on the population, monitoring and endpoint definition, so they should not be treated as a personal prediction or directly compared across different studies. [6][7]
Can I stop anticoagulation after AF ablation?
Do not stop it on your own. ESC guidance bases continued anticoagulation on individual thromboembolic risk, regardless of whether a person is in AF or normal rhythm. Discuss the plan with your treating clinician and arrange follow-up access to prescriptions before returning home. [9]
Can I travel abroad for urgent heart symptoms?
Suspected heart-attack symptoms require emergency care where you are. Do not delay seeking help to arrange an overseas consultation or flight. Planned international evaluation is a separate process that requires clinical confirmation of stability and travel suitability; it is not an emergency treatment pathway. [11][13]
Explore your next step
Sources
- 2023Chinese guideline for the clinical application of transcatheter aortic valve replacement
- NMPA · 19 February 2025Prizvalve Transcatheter Aortic Valve System Approved for Marketing
- Frontiers in Cardiovascular Medicine · 2023TAVR with the VenusA-Pro and VenusA-Plus systems: preliminary experience in China
- JACC · 2018Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial
- European Heart Journal · 2020The DEFINITION II trial
- JACC · 2025InsightPFA Trial
- Europace · 2024The PLEASE-AF study
- 2024Chinese expert consensus on perioperative nursing of transcatheter aortic valve replacement
- ESC · 2024Essential messages from the guidelines for the management of atrial fibrillation
- NHLBIStents: After You Get a Stent
- NHLBIHeart Attack Symptoms
- NHLBITranscatheter Aortic Valve Replacement
- CDC Yellow BookMedical Tourism
- Biomedical and Environmental Sciences · 2026Report on Cardiovascular Health and Diseases in China 2025: An Updated Summary